Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Next Previous
X
Search
Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegipanermin (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MINDFuL
  • Sponsors INmune Bio

    • Most Recent Events

    • 30 Sep 2024 According to an INmune Bio Media Release, company announced that it has closed enrollment for this trial.Enrollment of new patients into the trial was concluded after the Company determined that there are sufficient patients currently in screening to meet the trials target of 201 patients. All patients currently in the screening process will remain eligible to participate in AD02, which will likely result in modest over enrollment.
    • 17 Sep 2024 According to an INmune Bio Media Release, company expects to complete enrollment near the end of this quarter and will announce topline data approximately six months from the last patient enrolled.
    • 17 Sep 2024 Interim results presented in an INmune Bio Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top